CompletedPhase 3ACTRN12607000094471

Randomised control trial of monoamine precursors for the treatment of psychostimulant withdrawal

A double-blind, randomised, placebo controlled trial of monoamine precursors in the treatment of psychostimulant withdrawal in adult humans seeking treatment for psychostimulant use

Sponsor

Sydney South West Area Health Service

Enrollment

100 participants

Start Date

Jan 31, 2007

Study Type

Interventional

Conditions

Psychostimulant withdrawal

Summary

The study aims to: identify the safety and acceptability of monoamine precursor provision in the management of psychostimulant withdrawal; explore the impact of monoamine precursor provision on engagement and retention in treatment; research the effect of monoamine precursor provision on the clinical course and severity of psychostimulant withdrawal; and, explore the impact of monoamine precursor provision in improving abstinence rates.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 55 Yearss

Plain Language Summary

Simplified for easier understanding

This trial tests whether amino acid supplements (monoamine precursors) can help people going through withdrawal from stimulant drugs like amphetamines or cocaine. It is designed for adults aged 18 to 55 who are dependent on psychostimulants and are experiencing withdrawal symptoms. Participants will be randomly assigned to receive either the supplement or a placebo.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Oral monoamine precursors (5-HTP (300mg daily), L-tyrosine (1500mg daily), dl-phenylalanine (2000mg daily)) and oral multivitamins (3 tablets daily, one multivitamin tablet is on average in the range

Oral monoamine precursors (5-HTP (300mg daily), L-tyrosine (1500mg daily), dl-phenylalanine (2000mg daily)) and oral multivitamins (3 tablets daily, one multivitamin tablet is on average in the range of 1200mg – 1400mg). All participants will be offered 4 weekly sessions of outpatient cognitive behavioural therapy (CBT) of approximately one hour duration each.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000094471